Research Article
Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer
Table 1
Diagnosis and treatment process.
| | Date | Treatment | Tumor size, lymph nodes, distance transfer, and other data | Clinical response |
| | 01/22/2020 (01.16–01.23) | ddAC | One mass at 3 points on the left breast, about 4.0 3.9 cm in size | ADM (NA) | | One mass on the left axillary lymph node, about 2.0 3.0 cm in size | CTX (NA) | | No distant metastasis | | | 03/04/2020 | ddAC | No palpable tumor on the left breast and the left axillary lymph node | ADM (PR) | | CTX (PR) | | 05/20/2020 | ddT (The last time) | No palpable tumor on the left breast and the left axillary lymph node | DX (SD) | | 06/10/2020 (06.03–06.24) | Modified radical mastectomy | ypT1cN1M0 | | | 07/162020 | Endocrine therapy | Headache, dizziness, and syncope twice at home | Tamoxifen (NA) | | 09/21/2020 (09.21–09.23) | Tumor endocrine therapy | Cervical lymph node metastasis | Tamoxifen (PD) | | 09/25/2020 (09.25–10.09) | NP (vinorelbine + cisplatin) | Systemic metastases (bone, liver, lung) | Vinorelbine (SD) | | Cisplatin (SD) | | 11/11/2020 (11.11-11.24-11.27) | Methotrexate | Brain metastasis, death | Methotrexate (PD) |
|
|
ADM, adriamycin; DX, docetaxel; CTX, cyclophosphamide; NA, not analyzed; PR, partial response; SD, stable diseases; PD, progressive diseases.
|
